VolitionRx (NYSE:VNRX) Upgraded at Jones Trading

Jones Trading upgraded shares of VolitionRx (NYSE:VNRX) to a strong-buy rating in a research report sent to investors on Tuesday, Marketbeat Ratings reports. They currently have $3.00 price target on the stock.

VNRX has been the topic of several other reports. Wall Street Zen began coverage on VolitionRx in a report on Thursday, May 15th. They set a “sell” rating on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 target price on shares of VolitionRx in a research report on Wednesday, April 30th. Finally, HC Wainwright initiated coverage on VolitionRx in a research report on Tuesday, April 8th. They set a “buy” rating and a $2.50 target price on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, VolitionRx currently has a consensus rating of “Moderate Buy” and a consensus target price of $3.50.

VolitionRx Stock Performance

Shares of NYSE VNRX opened at $0.60 on Tuesday. The business’s 50 day moving average price is $0.50 and its 200-day moving average price is $0.57. VolitionRx has a fifty-two week low of $0.40 and a fifty-two week high of $0.90. The company has a market cap of $61.40 million, a price-to-earnings ratio of -1.66 and a beta of 1.07.

Insider Buying and Selling at VolitionRx

In other VolitionRx news, CEO Cameron John Reynolds acquired 181,818 shares of the stock in a transaction dated Wednesday, March 26th. The stock was purchased at an average price of $0.55 per share, with a total value of $99,999.90. Following the transaction, the chief executive officer now directly owns 2,299,222 shares of the company’s stock, valued at $1,264,572.10. This trade represents a 8.59% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders have purchased 271,818 shares of company stock valued at $141,100. 10.40% of the stock is currently owned by corporate insiders.

Institutional Trading of VolitionRx

A number of institutional investors have recently made changes to their positions in the business. Northern Trust Corp lifted its position in VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after acquiring an additional 28,579 shares during the period. Lagoda Investment Management L.P. lifted its position in VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after acquiring an additional 1,481,000 shares during the period. Two Sigma Securities LLC acquired a new stake in VolitionRx during the 4th quarter worth about $29,000. Finally, Millennium Management LLC acquired a new stake in VolitionRx during the 4th quarter worth about $36,000. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.